MarketCap
Facebook
X
Telegram
Kala Pharmaceuticals Net Debt | KALA
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Kala Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -30.7 M | -16.4 M | -32.5 M | -12.5 M | 1.65 M | 15.7 M | -71.5 M | -95.9 M | -35.8 M | 4.04 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15.7 M | -95.9 M | -27.4 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ESSA Pharma
EPIX
|
-103 M | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
17.3 M | - | - | $ 344 M |  USA |
 |
Clearside Biomedical
CLSD
|
-19.3 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-283 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-165 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
-136 M | $ 4.2 | -0.36 % | $ 651 M | USA |
 |
AbbVie
ABBV
|
59.5 B | $ 294.72 | 0.32 % | $ 521 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-1.97 M | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | USA |
 |
Achieve Life Sciences
ACHV
|
-9.68 M | $ 6.78 | 0.89 % | $ 296 M | USA |
 |
Axon Enterprise
AXON
|
536 M | $ 316.97 | 4.77 % | $ 24.7 B | USA |
 |
TFF Pharmaceuticals
TFFP
|
-5.36 M | - | -60.05 % | $ 125 K | USA |
 |
Bristol-Myers Squibb Company
BMY
|
32.8 B | $ 62.89 | 0.18 % | $ 128 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-36.2 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Axcella Health
AXLA
|
1.5 M | - | -16.42 % | $ 249 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
143 M | $ 58.59 | 4.29 % | $ 7.04 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-65.3 M | - | - | $ 2.02 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 159.75 | 5.35 % | $ 20.9 B | USA |
 |
Amgen
AMGN
|
41 B | $ 467.97 | 0.59 % | $ 252 B | USA |
 |
Orgenesis
ORGS
|
157 K | - | -33.86 % | $ 61.2 M | USA |
 |
Codiak BioSciences
CDAK
|
-39.4 M | - | -55.98 % | $ 2.15 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
2.95 B | $ 248.31 | 1.17 % | $ 15.1 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
21.7 B | $ 280.31 | -0.17 % | $ 675 B | USA |
 |
BioLineRx Ltd.
BLRX
|
-2.04 M | $ 1.49 | -1.97 % | $ 3.67 B | Israel |
 |
Sage Therapeutics
SAGE
|
-69.2 M | - | - | $ 527 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-5.46 M | $ 1.59 | -2.76 % | $ 2.62 M | Israel |
 |
Lineage Cell Therapeutics
LCTX
|
-39.9 M | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
223 M | - | - | $ 121 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-7.6 M | - | - | $ 58.1 M | USA |
 |
C4 Therapeutics
CCCC
|
-14.6 M | $ 2.9 | -3.5 % | $ 240 M | USA |
 |
Eli Lilly and Company
LLY
|
33.8 B | $ 1 437.4 | 0.36 % | $ 1.29 T | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-13.8 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Compugen Ltd.
CGEN
|
-87.6 M | $ 2.09 | -0.24 % | $ 195 M | Israel |
 |
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-53 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
GeoVax Labs
GOVX
|
-2.24 M | $ 2.13 | -20.4 % | $ 2.04 M | USA |
 |
Unity Biotechnology
UBX
|
16 M | - | -33.41 % | $ 3.37 M | USA |
 |
MediciNova
MNOV
|
-30.6 M | $ 1.41 | 0.36 % | $ 69.2 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-61.1 M | - | - | $ 521 M | USA |
 |
Seelos Therapeutics
SEEL
|
11.2 M | - | -47.76 % | $ 6.27 M | USA |
 |
Celldex Therapeutics
CLDX
|
-26.5 M | $ 30.18 | -1.53 % | $ 2 B | USA |
 |
Moderna
MRNA
|
-1.99 B | $ 248.62 | -0.88 % | $ 96.7 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-2.74 M | $ 3.96 | 1.41 % | $ 48.3 M | Israel |
 |
Kiromic BioPharma
KRBP
|
-224 K | - | 6.61 % | $ 3.08 M | USA |
 |
Nektar Therapeutics
NKTR
|
70.6 M | $ 38.41 | 1.67 % | $ 648 M | USA |
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | USA |
 |
CorMedix
CRMD
|
-143 M | $ 5.31 | -2.23 % | $ 383 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-141 M | $ 45.39 | 0.53 % | $ 4.08 B |  Schweiz |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
-3.29 M | $ 1.66 | -2.64 % | $ 1.12 B | Israel |